Benzinga | Aug 28, 2020 07:15AM EDT

Roth Capital Reinstates Buy on Enanta Pharmaceuticals, Announces $104 Price Target

Roth Capital analyst Zegbeh Jallah reinstates Enanta Pharmaceuticals (NASDAQ:ENTA) with a Buy and announces $104 price target.